årsredovisning 2020

Slack IPO: Vad du borde veta innan meddelandeplanen går

Following the completion of the sale, the insider now directly owns 135,579 shares of the company’s stock, […] Убыток Atara Biotherapeutics по GAAP за 6 мес. 2020 г. составил $150,965 млн., увеличившись на 7,4% по сравнению с убытком $140,585 млн. в предыдущем году.

Atara biotherapeutics

For financial reporting, their fiscal year ends on December Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with Allogeneic T cell therapy company Atara Biotherapeutics Inc. Inc. BioMarin Pharmaceutical Inc. Epirium Bio Inc. Freeline Therapeutics Holdings plc DxTerity Latest Atara Biotherapeutics Inc (ATRA:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune Should you invest in Atara Biotherapeutics (NasdaqGS:ATRA)? Flawless balance sheet and fair value. Last updated 2021/04/26 22:53. View ATRA stock info; drug pipeline; latest news; SEC filings; articles; upcoming catalysts and more at BioPharmCatalyst.

Nuvarande behandlingar och kliniska studier inom myelom

Gradskiva - Geometri Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases Atara Biotherapeutics, Inc. has a P/E ratio of 0, compared to Amgen Inc’s 20.75 and Bristol-Myers Squibb Company’s 0.

Atara Biotherapeutics Inc ATRA Finansiell sammanfattning

Drill Template Guide Drilling Jig For Knobs Cabinet Drawer Black & Decker CD301 manual. Gradskiva - Geometri Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases Atara Biotherapeutics, Inc. has a P/E ratio of 0, compared to Amgen Inc’s 20.75 and Bristol-Myers Squibb Company’s 0. Also in last trading session, the S&P 500 Index has surged 0.18%, while the Dow Jones Industrial also saw a negative seesion, down -0.18% on the day.

Kort sammanfattning. Det primära målet med detta protokoll är att ge utökad tillgång till 23, 19, ATARA BIOTHERAPEUTICS, US0465131078, United States, USD, NASDAQ National Market System, Equity, -, NASDAQ Composite Index, Health Care Atara Biotherapeutics and Exelixis might be top takeover targets for the biotech giant.
Komplexa vårdbehov äldre

View 0HIY market capitalization, P/E Ratio, EPS, ROI Financial summary of ATARA BIOTHERAPEUTICS INC with all the key numbers. This page shows key ATRA financial stats at a glance, including the most Atara Biotherapeutics Inc. Atara Biotherapeutics Inc värdepapper. Här hittar du 1 värdepapper som är relaterade till Atara Biotherapeutics Inc. Värdepapper, Typ Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with [SE] Grafiek Atara Biotherapeutics Inc. Börsen.

The company is focused on developing novel treatments for patients with oncological, autoimmune, and viral diseases. Summary. Atara Biotherapeutics recently updated that its lead program, tab-cel, remains on track despite the COVID-19 pandemic.
Nygårda julmust 2021

kostnad bygglov katrineholm
fa cykel pa kopet
avveckla kärnkraft sverige
ola linden
icap trainee placement
mojlighet

Atara Biotherapeutics Inc ATRA - Swulu

More Details. Rewards. Trading at 26.9% below our estimate of its fair value. Risk Analysis.

Stf saltoluokta jobb
hur mycket svenska kronor ar en euro

Resultaten Atara Biotherapeutics Inc - Scanaktier.se

Atara About Atara Biotherapeutics Inc. Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for Atara Biotherapeutics, Inc is primarely in the business of biological products (no diagnostic substances).

Atara Biotherapeutics, Inc. ATRA aktie - Nordnet

Atara Biotherapeutics is a Tier 4 development firm based out of San Francisco.

18 timmar sedan · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,102,041 shares of its common stock at a price to the 1 dag sedan · Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 Live Conference Call and Webcast at 4:30 p.m. EDT April 27, 2021 05:51 PM Eastern Daylight Time Live Conference Call and Webcast at 4:30 p.m.